What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

Amgen has a long track record of producing market-beating shareholder returns. Its newer drugs and biosimilars offer plenty of promise, and management has maintained aggressive share buybacks.
moderately positive